Although the effects of the IRA on our business and the healthcare industry in general are not yet known, we are taking into consideration the potential impact of the IRA on our development and commercialization activities.
All entries for: Endocrinology
February 24, 2026
Merck & Co., Inc.
Neutral Outlook
Rahway, NJ
10,000+ employees
The long-term implications of the IRA remain uncertain and subject to various factors, including the manner in which HHS decides to implement the statute. Many experts and analysts, both within the industry and outside, have predicted that the law will harm innovation in the pharmaceutical industry and result in fewer new treatments being developed and approved over time.
Disease Area: Endocrinology, Immune Diseases, Neurological Diseases, Oncology
Drug Type: Small Molecule
February 11, 2026
Neurocrine Biosciences Inc
Negative Outlook
San Diego, CA
1,000-5,000 employees
Most recently, in August 2022, the Inflation Reduction Act of 2022 (IRA) was signed into law… Lower negotiated prices for AUSTEDO and AUSTEDO XR may increase competitive pressures on INGREZZA, including heightened pricing pressure and potential adverse effects on formulary coverage.
Disease Area: Endocrinology, Multiple, Neurological Diseases, Psychiatry
Drug Type: Biologic, Small Molecule
January 14, 2026
EMD Serono
Layoffs
Boston, MA
1,001-5,000 employees
EMD Serono, the U.S. division of Merck KGaA, is parting ways with an undisclosed number of employees. The layoffs will affect research staff at the company’s offices in Durham, North Carolina.
Disease Area: Endocrinology, Immune Diseases, Neurological Diseases, Oncology
Drug Type: Small Molecule
November 4, 2025
Rhythm Pharmaceuticals
Neutral Outlook
Boston, MA
201-500 employees
Most significantly, in August 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010.
Disease Area: Endocrinology, Metabolic Diseases, Multiple, Rare Diseases
Drug Type: Small Molecule
November 4, 2025
Vertex Pharmaceuticals
Neutral Outlook
Providence, RI
5,001-10,000 employees
We cannot, however, predict how changes in the law, including through the Inflation Reduction Act of 2022 and passage of state laws (e.g., transparency laws and prescription drug affordability boards), will affect our ability to negotiate successfully with third-party payors and distribute our products.
Disease Area: Endocrinology, Hematology, Multiple, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
November 3, 2025
Rhythm Pharmaceuticals
Negative Outlook
Boston, MA
201-500 employees
IMCIVREE is not currently reimbursed under Medicare Part D, but if we were to be reimbursed under Medicare Part D in the future, the reimbursement amount will be impacted by the 10 and 20 percent discounts under the IRA’s new discounting program. We anticipate that these increased discounts could impact IMCIVREE revenues, while also having an industry-wide impact on the cost of Part D drugs. The impact on IMCIVREE revenues could be offset because the IRA’s redesign of certain Part D components, some of which went into effect in 2024, resulted in an increase in the number of patients able to afford this therapy. The amount of the offset, if any, is inherently uncertain and difficult to predict.
Disease Area: Endocrinology, Metabolic Diseases, Multiple, Rare Diseases
Drug Type: Small Molecule
October 28, 2025
Neurocrine Biosciences Inc
Negative Outlook
San Diego, CA
1,000-5,000 employees
Enacted healthcare reform, drug pricing measures and other recent legislative initiatives, including the Inflation Reduction Act of 2022 (IRA), could adversely affect our business.
Disease Area: Endocrinology, Multiple, Neurological Diseases, Psychiatry
Drug Type: Biologic, Small Molecule
October 10, 2025
Ferring Pharmaceuticals
Layoffs
Saint-Prex, Switzerland
5,001-10,000 employees
Privately held Ferring Pharmaceuticals will part ways with up to 500 employees across its global operations in a bid to “sharpen” its strategic focus and gain “flexibility” as a company. The layoffs will mean an approximately 7% headcount reduction.
Disease Area: Endocrinology, Gastrointestinal, Hematology, Oncology
Drug Type: Biologic, Small Molecule